The pathophysiological function of peroxisome proliferator-activated receptor-gamma in lung-related diseases.
Research into respiratory diseases has reached a critical stage and the introduction of novel therapies is essential in combating these debilitating conditions. With the discovery of the peroxisome proliferator-activated receptor and its involvement in inflammatory responses of cardiovascular disease and diabetes, attention has turned to lung diseases and whether knowledge of this receptor can be applied to therapy of the human airways. In this article, we explore the prospect of peroxisome proliferator-activated receptor-gamma as a marker and treatment focal point of lung diseases such as asthma, chronic obstructive pulmonary disorder, lung cancer and cystic fibrosis. It is anticipated that peroxisome proliferator-activated receptor-gamma ligands will provide not only useful mechanistic pathway information but also a possible new wave of therapies for sufferers of chronic respiratory diseases.
Huang
Tom Hsun-Wei
TH
Faculty of Pharmacy, A15, University of Sydney, New South Wales, 2006, Australia. tomh@pharm.usyd.edu.au
Razmovski-Naumovski
Valentina
V
Kota
Bhavani Prasad
BP
Lin
Diana Shu-Hsuan
DS
Roufogalis
Basil D
BD
D000818:Animals; D006801:Humans; D008168:Lung / Q000276:immunology* / Q000378:metabolism*; D008171:Lung Diseases / Q000276:immunology* / Q000378:metabolism*; D047495:PPAR gamma / Q000276:immunology* / Q000378:metabolism*
D047495:PPAR gamma